Richard S. Finn, MD / Laura M. Kulik, MD - Rethinking Care in Hepatocellular Carcinoma Amid Expanding Treatment Options: An Interdisciplinary Discussion

Go online to PeerView.com/PDD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a multidisciplinary panel of interventional radiology, hepatology, and medical oncology experts provide an in-depth analysis of the latest data for approved and emerging systemic treatment options and recent evidence on locoregional and multimodal approaches for patients with HCC. In addition, the expert panel provides guidance on strategies to optimally select and timely transition between locoregional and systemic therapies. Upon completion of this activity, participants should be better able to: Summarize recent evidence on the treatment role, efficacy, and safety of approved and emerging immunotherapeutic and targeted systemic options for patients with newly diagnosed and previously treated HCC, Cite recent clinical evidence on locoregional and multimodal approaches in patients with intermediate-stage HCC, Select optimal therapies, including in the context of clinical trials, for patients with intermediate-stage or advanced HCC, with considerations of patient- and disease-related factors, underlying liver disease, and timely transitions between locoregional and systemic options.